
    accrual too slow, insufficient patients
  
['myelodysplastic syndromes']
['deferasirox + azacitidine', 'azacitidine']

        Inclusion Criteria:

          -  Adults >18 yrs of age

          -  WHO defined MDS with Higher risk MDS (IPSS int-2/high)

          -  Azacitidine X at least 6 cycles with no hematologic improvement/no disease progression
             as per IWG 2006 criteria

          -  Ferritin >500 µg/L

          -  If transfusion independent, must have Hb <110 g/L OR Neutrophils < 1,000/mL OR
             Platelets < 100,000/mL

          -  ECOG ≤2

          -  CrCl >40 ml/min

        Exclusion Criteria:

          -  Increased ALT (>300 U/L)

          -  Uncontrolled infection

          -  HIV+

          -  Pregnant or breast-feeding

          -  Previous and concurrent iron chelation

          -  Concurrent use of hematopoietic growth factors including erythropoietin, darbepoietin
             and granulocyte colony stimulating factor

          -  Concurrent use of other disease modifying agents including cytotoxic chemotherapy,
             histone deacetylase inhibitors, other hypomethylating agents or lenalidomide
      